Practical Hematologist is pleased to present a complimentary live webinar for the
multidisciplinary hemophilia treatment team. Join us for this educational event and earn 1.0 LIVE CME, CPE, or CNE credit.
CHOOSE FROM ONE OF THE FOLLOWING SESSIONS Click the appropriate button below to register
Steven W. Pipe, MD – Chair Professor of Pediatrics and Pathology
Laurence A. Boxer Research Professor of
Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and
Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, Michigan
Janice M. Staber, MD Associate Professor of
University of Iowa
Carver College of Medicine
Stead Family Department of Pediatrics
Iowa City, Iowa
Courtney D. Thornburg, MD Director,
Thrombosis Treatment Center
Rady Children’s Hospital
Professor of Pediatrics
University of California - San Diego
San Diego, California
Annette von Drygalski, MD, PharmD, RMSK Professor of Clinical Medicine
Director, Hemophilia and Thrombosis
Treatment Center Director, Coagulation Fellowship
Associate Program Director, Hematology Fellowship
University of California
San Diego, California
Gene therapy (GT) is becoming an increasingly important therapeutic option for patients with hemophilia, with the potential to transform lives. Gene therapy is inherently different from conventional treatments in that it offers potential life-long cures by correcting for the missing or mutated genes that underlie genetic diseases, such as hemophilia. This activity will discuss the implications of gene therapy in the management of patients as well as current clinical trial data on gene therapy in hemophilia. Our goal is to provide you with the most up-to-date information to allow you to improve your confidence and competence in your ability to implement gene therapy with an integrated care delivery model in your treatment center.
This program will conclude with a live question and answer session. Don’t miss the opportunity to ask your questions or share your clinical challenges directly with the experts.
Gene Therapy for the Treatment of Hemophilia
Utilizing an Integrated Care Model to Improve Outcomes
Summary of Key Points for Practice
Question and Answer Session
This activity is designed for multidisciplinary healthcare providers in the community setting, including hepatologists, hematologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with hemophilia A and B.
Learning Objectives Upon completion of this educational activity, participants should be able to:
Review gene and cell therapy and genome editing, including the fundamentals of adeno-associated virus (AAV)-mediated, liver-directed gene transfer
Describe current and emerging gene therapies for the treatment of hemophilia A and B, including data on the impact of preexisting AAV immunity against vectors used in hemophilia gene therapy strategies, as well as the development of new strategies for the treatment of patients with preexisting neutralizing antibodies (NAbs)
Discuss strategies for providing sufficient information about screening, delivering, and monitoring gene therapy and its sequelae, as well as providing guidance for making informed decisions regarding gene therapy
Outline the hub and spoke model approach to gene therapy administration, including key roles and responsibilities for clinicians and practical approaches to implementation
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hoursof Continuing Education Credit. Universal Activity Number: 827-0000-22-020-L01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 22-020-158
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship.
All relevant conflicts of interest have been mitigated prior to the commencement of this activity.
Dr. Steven Pipe has relevant financial relationships related to advisory activities from GeneVentiv Therapeutics and consulting from ApcinteX, now a Centessa Company, ASC Therapeutics, Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring, Freeline Therapeutics, Genentech - A Member of the Roche Group, GeneVentiv Therapeutics, HEMA Biologics, LLC, Novo Nordisk A/S, Pfizer Inc., Regeneron Pharmaceuticals, Inc./Intellia Therapeutics, Inc., Sanofi, Spark Therapeutics, Inc., Takeda Pharmaceutical Company Limited, and uniQure N.V. He has received research grant(s) from Siemens.
Dr. Janice Staber has relevant financial relationships related to advisory activities from Bayer AG, CSL Behring, and Sanofi.
Dr. Courtney Thornburg has relevant financial relationships related to consulting activities from CSL Behring, Genentech - A Member of the Roche Group, HEMA Biologics, LLC, Octapharma USA, Inc., Sanofi, and Takeda Pharmaceutical Company Limited. She has received grant funding from BioMarin Pharmaceutical Inc. and is a member of Data and Safety Monitoring Boards for bluebird bio, Inc. and Cyclerion Therapeutics, Inc.
Dr. Annette von Drygalski has relevant financial relationships related to advisory activities from ASC Therapeutics, BioMarin Pharmaceutical Inc., Bioverativ Inc./Sanofi, CSL Behring, Genentech - A Member of the Roche Group, Novo Nordisk A/S, Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and uniQure N.V.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, and Jodi Andrews, Director of Operations, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Instructions for Participation and Credit
There are no fees for participating in this activity.
In order to receive credit, all participants must complete the post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.
CME and CNE Credit certificates will be emailed 4 weeks following receipt of completed requirements.
CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation
If you have any questions regarding the content of this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x130 or [email protected].
Supported by an educational grant from BioMarin Pharmaceutical Inc.